Armata Pharmaceuticals, Inc. (ARMP) AI Stock Analysis

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing targeted bacteriophage therapeutics to treat antibiotic-resistant infections globally. Utilizing its proprietary bacteriophage platform, the firm focuses on addressing critical medical challenges. Key product candidates include AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 targeting Pseudomonas aeruginosa infections, and AP-PA03 for pneumonia treatment. In addition, Armata has established strategic partnerships, including a collaboration with Merck & Co. to develop synthetic bacteriophage candidates against undisclosed infectious disease agents. Headquartered in Marina del Rey, California, the company operates with 61 employees.

Armata's revenue grew at a 5-year compound annual growth rate of 42.9% from FY2020 to FY2025. Annual revenue shifted from $4.5M in FY2021 to $5.5M in FY2022, followed by $4.5M in FY2023, $5.2M in FY2024, and $4.9M in FY2025, when revenue fell 5.2%. Profitability remained negative, with net income worsening to -$173.8M in FY2025 from -$18.9M in FY2024, resulting in a net margin of -3544.0%. For the latest quarter ended June 30, 2026, quarterly revenue grew 15.7% year-over-year. Over the trailing twelve months, revenue reached $5.5M, while the operating margin stood at -410.8% and EPS was -$5.29.

As of June 30, 2026, Armata held $24.0M in cash and short-term investments alongside total debt of $314.0M, resulting in net debt of $290.0M. The company reported negative shareholders' equity of -$231.2M and total assets of $90.0M, with a current ratio of 0.11. Operating cash flow was -$25.8M and free cash flow was -$26.3M in FY2025. In FY2025, capital expenditures totaled $542,000, while the company's share count increased by 135.9% over five years.

At a share price of $3.37, Armata carries a market capitalization of $125.3M and an enterprise value of $446.2M. The stock trades at a price-to-sales multiple of 22.6x and an EV-to-EBITDA multiple of 14.4x, higher than the medians of its US-listed Healthcare peers at 4.1x and 12.0x, respectively. The company's price-to-book ratio is 2.1x. Over the past year, the stock declined 3.4%, underperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 2.3% compared to an 83.0% gain for the benchmark.

Armata has 1 Buy rating and 0 Hold or Sell ratings from analysts. The mean price target is $17.50, representing an upside of 419.3% from the last close of $3.37. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $4.2M and an EPS of -$1.86. For the following fiscal year, 2 analysts project revenue of $2.8M, representing a 35.3% revenue decline, and an EPS of -$1.45. Armata beat EPS estimates in 2 of the last 4 quarters, with the next earnings release scheduled for November 11, 2026.

This page is an AI-written research summary of Armata Pharmaceuticals, Inc. (ARMP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARMP income statement, ARMP balance sheet, ARMP key metrics, ARMP analyst forecast, ARMP chart. See the ARMP stock overview for the latest quote and news.